Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat

British Journal of Pharmacology
Asami UminoT Nishikawa

Abstract

1. We have investigated the effects of a schizophrenomimetic drug phencyclidine (PCP) and N-methyl-D-aspartate (NMDA)-related agents alone or in combination on dopamine metabolism in the medial prefrontal cortex and striatum of the rats by measuring the tissue concentrations of dopamine and its metabolite, 3,4-dihyroxyphenylacetic acid (DOPAC), and the rate of dopamine disappearance (dopamine utilization) after its synthesis inhibition. 2. Systemic injection of PCP and selective, non-competitive, NMDA antagonists caused an increase of both tissue concentrations of DOPAC and dopamine utilization in the prefrontal cortex but not in the striatum. The PCP-induced augmentation of cortical dopamine metabolism was not influenced by selective lesion of ascending noradrenergic neurones. 3. Intra-prefrontal cortical infusion of PCP or selective competitive or non-competitive antagonists of the NMDA receptor mimicked the ability of systemic PCP injection to enhance DOPAC levels and dopamine utilization in the prefrontal cortex. However, an NMDA antagonist injected into the cell body area of the mesocortical dopaminergic neurones failed to affect dopamine metabolism in the prefrontal cortex. 4. The increasing effects of PCP and selective N...Continue Reading

References

Sep 3, 1976·Brain Research·D H VersteegM Palkovits
Feb 1, 1991·Journal of Neurochemistry·T MauriceR Chicheportiche
Jan 1, 1991·Physiological Reviews·M Le Moal, H Simon
Feb 1, 1989·Clinical Neuropharmacology·S I DeutschJ M Morihisa
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley

❮ Previous
Next ❯

Citations

Sep 13, 2005·Biological Psychiatry·Guochuan E TsaiMian-Yoon Chong
Dec 15, 2000·Progress in Neurobiology·T M Tzschentke
Oct 20, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shuichi HiraokaToru Nishikawa
Aug 19, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Naoki YamamotoToru Nishikawa
Sep 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tohru Ohnuma, Heii Arai
Mar 4, 2009·The International Journal of Neuropsychopharmacology·Hironao TakebayashiToru Nishikawa
Mar 8, 2007·Journal of Pharmacological Sciences·Kenji MaedaKiyofumi Yamada
Sep 6, 2005·Biological & Pharmaceutical Bulletin·Toru Nishikawa
Jul 9, 2020·Biochimica Et Biophysica Acta. Proteins and Proteomics·Cindy J LeeJonathan V Sweedler
Oct 14, 2011·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Toru Nishikawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.